Video

Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

Author(s):

Solange Peters, MD, PhDMelissa Johnson, MD

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.

Related Videos
Nicolas Girard, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Shirish M. Gadgeel, MD
Jacob Sands, MD
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Charu Aggarwal, MD, MPH, FASCO
Related Content
FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
October 3rd 2024

FDA Approves Perioperative Nivolumab for Resectable NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.
September 28th 2024

The OncFive: Top Oncology Articles for the Week 9/22

FDA
September 25th 2024

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation